Anakinra as first‐line disease‐modifying therapy in systemic juvenile idiopathic arthritis: Report of forty‐six patients from an international multicenter series

A. Nigrovic, Peter; Mannion, Melissa; H. M. Prince, Femke; Zeft, Andrew; Egla Rabinovich, C.; A. J. van Rossum, Marion; Cortis, Elisabetta; Pardeo, Manuela; M. Miettunen, Paivi; Janow, Ginger; Birmingham, James; Eggebeen, Aaron; Janssen, Erin; I. Shulman, Andrew; Beth Son, Mary; Hong, Sandy; Jones, Karla; T. Ilowite, Norman; Q. Cron, Randy; C. Higgins, Gloria

doi:10.1002/art.30128

Public

Anakinra as first‐line disease‐modifying therapy in systemic juvenile idiopathic arthritis: Report of forty‐six patients from an international multicenter series

Shared by NobleBlocks on Jan 28, 2011 • 12:00 AM UTC

Authors:

Peter A. Nigrovic

Melissa Mannion

Femke H. M. Prince

Abstract

Abstract Objective To examine the safety and efficacy of the interleukin‐1 (IL‐1) receptor antagonist anakinra as first‐line therapy for systemic juvenile idiopathic arthritis (JIA). Methods Patients with systemic JIA receiving anakinra as part of initial disease‐modifying antirheumatic drug (DMARD)...

Discussions